Founded in 1990, Corgenix Medical Corporation is based in Colorado, with an international marketing office in the United Kingdom. The Colorado facility is engaged in research, development, manufacture, and marketing of in vitro diagnostic products for use in disease detection and prevention. Corgenix is committed to providing innovative and quality medical products to meet the needs of the ever-changing healthcare field. We believe our vision and commitment will place our company at the forefront to meet the needs of the ever-changing healthcare field..

Most of the company’s products are based on a patented and proprietary application of Enzyme Linked ImmunoSorbent Assay (ELISA) technology, a common clinical testing methodology used worldwide. Products developed using the patented unique attachment methodology are typically more uniform and a more stable than those of our competitors. The company pioneered the field of antiphospholipid antibody detection with the development of the first FDA-cleared assay for measuring anticardiolipin antibodies, and through continued research and development, is recognized worldwide as an innovator and opinion leader in this arena. The association of antiphospholipid antibodies with thrombosis inspired the company to develop additional assays for the evaluation of certain bleeding and clotting disorders.

Corgenix expertise, strong quality system, solid infrastructure, expert staff, and state of the art manufacturing facility have attracted partners ranging from small start-up companies and universities to large biotechnology corporations. As a small company, Corgenix can respond quickly to the needs of our partners and dedicate the best minds to their projects. Corgenix provides contract services including product development, regulatory submission (US, Europe and worldwide), manufacturing, customer service, sales, marketing and global product distribution. Corgenix offers critical competencies within a highly regulated industry.